Erlotinib plus bevacizumab versus erlotinib alone in patients with <i>EGFR</i>-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials.

ABSTRACT:

Objectives

Combination treatment with erlotinib plus bevacizumab has the potential to become a standard treatment regimen for patients with epidermal growth factor receptor mutation-positive (EGFRm⁺) advanced non-small cell lung cancer (NSCLC). This study aimed to investigate the efficacy and safety of erlotinib plus bevacizumab in patients with EGFRm⁺ advanced NSCLC.

Design

Systematic review and meta-analysis.

Data sources

The PubMed, Embase, Web of Science and Cochrane Library databases were searched, from inception to 15 January 2022.

Eligibility criteria

We included randomised controlled trials (RCTs), reported in English, assessing the efficacy of erlotinib plus bevacizumab versus erlotinib monotherapy in patients with <

SUBMITTER: Deng W 

PROVIDER: S-EPMC9396158 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature